Apoptosis-inducing agents
A compound, independent technology, applied in the disease field of Bcl-xL protein, can solve only weak binding, cytotoxicity and other problems
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[1074] N-(1,3-Benzothiazol-2-yl)-2-(4-{[(4-{[(2R)-4-(dimethylamino)-1-(phenylsulfanyl) But-2-yl]amino}-3-nitrophenyl)sulfonyl]carbamoyl}-1,3-thiazol-2-yl)-1,2,3,4-tetrahydroisoquinoline-8 - Formamide.
Embodiment 1A
[1076] 2-(8-(Benzo[d]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)thiazole-4-carboxylic acid
[1077] To 2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-8-carboxylic acid (6.8 g) and benzo[d]thiazol-2-amine (5.52 g) in di To a solution in methyl chloride (80 mL), add 1-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride (9.4 g) and 4-(dimethyl amino)pyridine (6 g). The mixture was stirred overnight, diluted with dichloromethane (400 mL), and washed with 5% aqueous HCl and brine. The organic layer was washed with Na 2 SO 4 Drying and concentration afforded the title product.
Embodiment 1B
[1079] (R)-4-(4-(Dimethylamino)-1-(phenylsulfanyl)butan-2-ylamino)-3-nitrobenzenesulfonamide
[1080] To a solution of Example 1A (8.5 g) in dichloromethane (80 mL) was added 2N HCl in ether (80 mL). The reaction mixture was stirred overnight and concentrated to give the title product.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 